Improved Survival in Patients with Multiple Myeloma Treated with DMVM plus IFN- α

Teruo Kitani, Yukihiro Tokumine, Tohru Masaoka, Atsushi Horiuchi, Eizo Kakishita, Takashi Kageyama, Noriyuki Tatsumi, Jun Kuyama, Kunio Hayashi, Machiko Tsukaguchi, Hiroya Kawagoe, Hedeki Fujitake, Tadahiro Tsubakio, Kaori Nasu, Yoshiteru Konaka, Tsuyoshi Yonezawa and Kiyoyasu Nagai.

for the Hanshin Study Group on Treatment for Hematological Disorders

We examined effects of combination chemotherapy with dexamethasone, melphalan, vincristine, and MCNU (DMVM), plus IFN- α in patients with previously untreated and treated multiple myeloma (MM). In the study, 78 previously untreated and 47 treated MM patients were evaluated. The overall response rate was 76% [27% complete response (CR)] : 85% [37% CR] in previously untreated patients and 62% [11% CR] in previously treated patients. The 50% survival time was 45.3 months for untreated patients and 30.1 months for previously treated patients. This regimen is effective in producing a high CR rate and prolonging survival duration of MM patients.

Key words DMVM+IFN- α , multiple myeloma

INTRODUCTION

Facilitated by therapeutic improvement in high-dose therapy followed by peripheral blood stem cell transplantation (PBSCT) for leukemias and lymphomas, PBSCT has been introduced in the therapy of for multiple myeloma (MM). In addition, since interferon (IFN)- α is known to be effective in MM, modified combination chemotherapy with IFN- α has been performed. Thus, treatment for MM includes chemotherapy, INF- α , radiation, bone marrow transplantation, and PBSCT¹. The progress in therapeutic outcome with these approaches has revealed that some proportion of MM patients may attain CR.

We developed a DMVM+IFN- α regimen that combines dexamethasone, melphalan, vincristine, and MCNU with IFN- α therapy. In a preliminary study, response rates for total 18 patients (8 untreated patients, 10 treated patients) showed were 69% and 38% for CR+PR and CR, respectively². The high response rate prompted us to perform this multicenter study in patients with previously untreated and treated MM.

MATERIALS AND METHODS

Patient selection and accrual

Eligibility required a diagnosis of MM confirmed by bone marrow plasmacytosis of at least 10% as well as documented M-protein in either serum or urine or characteristic osteolytic bone lesions. Measurable disease implied a serum M-protein level of greater than 3 g/dl, or urine monoclonal light chain excretion greater than 1 g/24 hr.

Staging was performed in accordance with to Durie-Salmon's criteria, in which patients with creatinine level less than 2 mg/dl are subclassified as A, and those with creatinine level not less than 2 mg/dl are subclassified as B. In our study, patients with creatinine level between 1.2 and 2 were commented as "stage A with mild renal dysfunction."

Study design

The DMVM+IFN- α therapy regimen was administered as follows : dexamethasone 40 mg/patient by drip infusion (d.i.) or orally (p.o.) on days 1-4, 9-12, and 17-20 ; melphalan 12 mg/patient p.o. on days 1-6 ; vincristine 1.2 mg/m² (max 2 mg) intravenously (i.v.) on day 1 ; MCNU 70 mg/patient i.v. on day 1 ; and IFN- α 3×10^6 IU/patient was administered intramuscularly on days 1-20. In cases that exhi-

Received : Dec 7, 2004

Revised : Jul 1, 2005

Accepted : Jul 1, 2005

Sakai Municipal Hospital, 1-1 Minamiyasui-cho, Sakai City, 590-0064, Osaka, Japan
Address correspondence and reprint request to Teruo Kitani, Sakai Municipal Hospital, 1-1 Minamiyasui-cho, Sakai City, 590-0064, Osaka, Japan

bited myelosuppression on day 12, IFN- α was sometimes withheld on investigator preference. The DMVM+IFN- α regimen was repeated two or three times every 6 or 8 weeks.

Dose modification

Chemotherapy was administered at full dose, except for patients aged 70 years or older, who began treatment with a 25% reduction in MCNU dosage. In patients with renal dysfunction, dosages were reduced on investigator preference.

Response criteria

Criteria for remission were as follows : complete remission (CR) referred to disappearance of M-protein or Bence-Jones protein, decrease to less than 5% of bone marrow plasma cells, and alleviation of symptoms due to MM (lumbago, bone pain, fatigue and palpitation) ; partial remission (PR) referred to a greater than 50% decrease in M-protein or Bence-Jones protein ; minor response (MR) was defined as a decrease between 25 and 50% ; no change (NC) was defined as less than 25% decrease. These responses must have persisted for at least 4 weeks.

Progressive disease referred to greater than 25% increase in M-protein or Bence-Jones protein. Progression of disease was defined as an increase of M-protein or Bence-Jones excretion by 50% above the previous nadir obtained during the best response to treatment. Response duration was determined as the time from attainment of response to the date of progression.

Statistical method

Two-tailed Fisher's exact test was used to compare CR rates between two groups. Survival distribution was estimated with Kaplan-Meier curves and compared by Log-Rank test.

Logistic regression analyses were performed to determine which variables were related to the effects (CR+PR).

P value less than 0.05 (2-tailed) was considered to indicate significance.

All analyses were performed with the use of SAS software (version 8.02, SAS Institute).

RESULTS

From 1989 to 1996, of 140 patients registered, 10 patients who did not fulfill the eligibility criteria were excluded from evaluation, and 5 patients were not evaluated because of early withdrawal from the assigned treatment due to the following adverse effects ; myelosuppression in 2 cases, and interstitial pneumonia, psychiatric reaction, and ventricular tachycardia in one case each. The remaining 125 patients were eligible. These included 78 previously untreated and 47 treated MM patients. All patients gave informed consent before being entered into the study. The patient characteristics are shown in Table 1.

The 50% duration of follow-up (from first DMVM+IFN- α administration to death, or to a 50% date last seen in the surviving patients) was 45.3 months for untreated patients and 30.1 months for previously treated patients.

Response

The response to therapy is summarized in Table 2. Of the previously untreated patients, 29 (37%) achieved CR and 37 (47%) achieved PR. Of the previously treated patients, 5 (11%) achieved CR and 24 (51%) PR. The difference in the CR rates between the two patient groups was significant (Chi-square $P=0.005$). The 50% response duration was 16.2, 19.7, and 12.7 months for untreated patients with CR+PR, CR, and PR, respectively. The 50% response duration was 10.1, 18.5, and 7.6 months for previously treated patients with CR+PR, CR, and PR, respectively.

Survival

The 50% survival time from the start of DMVM+IFN- α

Table 1. Characteristics of patients

Number of patients	125 (Number of eligible subjects)			
Age	31-84 years (Median 61)			
Sex	54 males, 71 females			
Stage	IA : 10 patients	IIA : 28 patients*	IIIA : 73 patients§	
	IB : 0 patients	IIB : 2 patients	IIIB : 12 patients	
Disease type	IgG κ : 49 patients	IgA κ : 10 patients	IgD κ : 0 patients	BJP κ : 7 patients
	IgG λ : 33 patients	IgA λ : 13 patients	IgD λ : 4 patients	BJP λ : 9 patients
Previous treatments	No 78,	Yes 47		

* Stage II with mild renal dysfunction : 2 patients

§ Stage III with mild renal dysfunction : 6 patients

Table 2. Clinical effects and stage of disease

Treatment/ Stage	Number of patients				Response rate (%)		
	CR	PR	MR		CR	CR+PR	CR+PR+MR
Total number of patients	125	34	61	25	27	76	96
Stage I	7	5	1	1	71	86	100
Stage II	18	6	10	1	33	89	94
Stage III	53	18	26	8	34	83	98
Previously untreated	78	29	37	10	37	85	97
Stage I	3	1	1	1	33	67	100
Stage II	12	1	9	2	8	83	100
Stage III	32	3	14	12	9	53	91
Previously treated	47	5	24	15	11	62	94

was 45.3 months for previously untreated patients and 30.1 months for previously treated patients (Fig. 1). For untreated patients, the 50% survival duration was 53.2 and 39.0 months for patients with CR and PR respectively (Fig. 2).

Response according to Ig isotype

Response in terms of Ig isotype was analyzed for all 125 patients. The CR rate increased to in the order of IgG (20%), IgA (26%), IgD (50%), and BJP (63%) (Table 3). The 50% duration of response (CR+PR) was 17.7, 17.5, and 10.6 months for patients with BJP, IgG, and IgA myeloma, respectively. The 50% survival time was 43.1, 47.8, and 24.6 months for patients with BJP, IgG, and IgA, respectively (Fig. 3).

Factors affecting response and survival

Factors affecting response (CR+PR) are shown in Table 4. For all patients, including previously treated patients, hemoglobin and platelets were associated with response.

With respect to Ig isotype, subdivision of patients into untreated and previously treated patients resulted in populations too small to investigate statistically.

Dose modification and response in patients with renal dysfunction

In patients with renal dysfunction, dosages were reduced on investigator preference. Table 5 shows the dose modification and creatinine levels during the first course of DMVM+IFN- α and the clinical effects in patients with stage B and mild renal dysfunction. In most cases, the creatinine level improved during the first course of therapy.

In some several cases, IFN- α was not administered : due

owing to refusal in 2 cases, and discontinued due owing to adverse effects in 3 cases. In these cases, DMVM alone also showed antitumor effects.

Toxicity

Side effects derived from characteristics of IFN- α were distinguished, especially subclinical fever and fatigue. These effects ameliorated gradually over time (Table 6). Myelosuppression, mainly due to DMVM regimen, was usually not severe. Thrombocytopenia requiring platelet transfusion was observed in 3 cases. Neutropenia below 1,000/ μ L was also observed, in 6 cases.

DISCUSSION

The authors devised a novel chemotherapeutic regimen for MM involving use of anticancer drugs shown to be beneficial in previous regimens combined with high-dose steroid hormone. This regimen includes melphalan, vincristine, MCNU, and dexamethasone. Melphalan and vincristine, a nitrosourea, were selected as alkylating agents. MCNU was substituted for BCNU, which is not commercially available in Japan. Dexamethasone was administered in the same manner as VAD therapy^{3,4}. Alexanian, *et al.* reported that in VAD therapy, which is known as an efficacious regimen, dexamethasone was most effective⁵. Vincristine was administered by bolus injection to facilitate administration procedures. Doxorubicin, which was not so effective in our previous regimen, was excluded from the present regimen.

IFN- α was first used as monotherapy in remission induction therapy and then in combination with chemotherapy. The combination regimen is subdivided into two types : concurrent use of IFN- α and chemotherapy, and alternating use. As Cooper, *et al.* have reported an additive action between

Fig. 1. Survival period of patients with and without previous treatments, from the beginning of induction therapy

Fig. 2. Survival of previously untreated patients, according to clinical response

Table 3. Clinical effects according to Ig isotype

Therapeutic effects	Number of Patients					Response rate (%)	
	CR	PR	MR	NC/PD		CR	CR+PR
IgG	82	16	42	21	3	20	71
IgA	23	6	12	4	1	26	78
IgD	4	2	2			50	100
BJP	16	10	5		1	63	94
All patients	125	34	61	25	5	27	76

Fig 3. Survival curves according to the Ig isotype

Table 4. Prognostic factors in DMVM+IFN- α therapy

Treatment	Factors related to effects (CR+PR)*			
	Univariate logistic regression analysis#		Multivariate logistic regression analysis#	
Previously untreated	N.S.		N.S.	
Previously treated	Hemoglobin	0.023	N.S.	
All patients	Hemoglobin	0.023	Hemoglobin	0.024
	Platelets	0.009		

P value.

IFN- α and chemotherapeutic drugs *in vitro*⁶, the former regimen was selected.

The present study demonstrated that DMVM+IFN- α therapy is an effective regimen achieving a high rate of response, including CR. There have been many reports of the therapeutic results of MP therapy, a standard chemotherapy for MM, since the report by Alexanian, *et al*⁷. Gregory reported, in summary, that the remission rate (PR or higher) was around 60% with CR rarely noted, and the average survival time was approx. 32 months⁸. In contrast, the present DMVM+IFN- α therapy produced a response rate of 76% including a CR rate of 27%, and a 50% survival time of 38.1 months. The remission effect was particularly high in untreated patients, with a response rate of 85% including a CR rate of 37%, while even in previously treated patients (mostly with MP therapy), the response rate was 62% including the CR rate of 11%. Furthermore, responders (CR+PR) showed improvement in quality of life (QOL) in association with alleviation of pain and fatigue as well as improvement in performance status.

The CR rate by disease type was 63% for BJP type, 26%

for IgA type, and 20% for IgG type. Given that the BJP and IgA type diseases are known to respond better to IFN- α than IgG type, the difference in the response rate among disease types may be attributable to IFN- α .

As with VAD therapy, the DMVM+IFN- α regimen includes high-dose dexamethasone. Among the reports on VAD therapy to date, the report by Alexanian showed that the original VAD therapy produced a response rate of 42%, with no indication of CR rate, and a median survival time of 36 months. VAD therapy provides rapid therapeutic effects, but is associated with early recurrence. Alexanian attributed the main effect of VAD to dexamethasone. The present authors suppose that the effect of dexamethasone persists only for a short duration and cannot be prolonged by other agents included in the VAD therapy (continuous infusion of doxorubicin and vincristine). Nevertheless, the a modified VAD regimen (dexamethasone not administered on days 9 to 12 and 17 to 20) achieved CR^{9,10}, which may have been made possible by early commencement of the next cycle of chemotherapy and increase in dose intensity.

A regimen involving the same combination of drugs as

Table 5. Effect of DMVM+IFN- α on renal dysfunction for stage B patients

Patient	Stage	Disease type	BJP (g/day)	Dose (%)					Creatinine (mg/ dl)			Effect
				Dex	MCNU	Vcr	Mel	IFN- α	Before treatment	Nadir	After 1 course	
HS	IIIB	BJP λ	ND	100	100	100	100	Daily	3.6	1.1	1.3	CR
SM	IIIB	BJP κ	21.8	100	100	100	100	Daily	3.3	1.4	1.5	CR
FT	IIB	IgG λ	$\pm$	50	100	100	100	Daily	3.3	1.2	1.2	CR
FM	IIIB	BJP κ	3.8	100	100	88	100	Dairy	2.9	2.8	2.8	CR
AN	IIIB	BJP κ	ND	100	100	100	100	Dairy	3.3	1.3	0.7	CR
SS	IIB	IgA λ	0.2	100	71	56	33	Every other day	2.2	1.8	2.4	CR
OH	IIA	BJP κ	3.1	50*	71	100	50	Daily	1.9	1.3	1.3	CR
YY	IIIA	IgA λ	+	100	100	100	100	Daily	1.8	0.7	0.8	CR
HK	IIA*	IgG λ	6.0	100	100	100	100	Daily	1.6	1.0	1.0	CR
TN	IIIA	IgG κ	ND	33	100	100	100	Daily	1.5	0.7	0.7	CR
MT	IIIA	IgG λ	ND	80	71	100	100	Every other day	1.2	0.9	0.9	CR
SF	IIIB	BJP κ	12.5	100	100	100	100	0	3.3	1.5	2.3	PR
MH	IIIB	IgG κ	ND	100	71	56	67	Daily	3.0	2.4	2.4	PR
MS	IIIB	BJP λ	1.8	75	71	100	33	Every other day	2.4	1.9	1.9	PR
MH	IIIB	IgA κ	2.3	100	100	100	100	Daily	2.3	0.9	0.9	PR
NY	IIIB	IgG κ	0.3	100	71	56	100	0#	2.1	0.9	1.1	PR
MK	IIIA	IgG λ	—	100	100	100	100	Daily	1.9	1.3	1.3	PR
YS	IIIA*	IgG κ	0.5	100	100	100	100	Daily	1.5	1.0	1.0	PR
ST	IIIA	IgA λ	0	100	100	100	100	Daily	1.3	1.1	1.1	PR
Mean									2.3	1.3	1.4	

Detailed data were not obtained for three patients. * Dose reduction due to diabetes mellitus. Therapy discontinued due to steroid myopathy. # IFN- α not used because of outpatient status. Eight patients with mild renal dysfunction (creatinine between 1.2 and 2.0) were included.

ours is the ROAD-IN therapy reported by Wada, *et al*¹¹. The ROAD-IN regimen has the same combination of drugs as the DMVM+IFN- α regimen, but differs in that the IFN- α therapy is administered sequentially after for 3 weeks following the DMVM therapy for the next 3 weeks. This regimen achieved a response rate of 75% (CR rate of 24%) and a median survival time of 3.6 years, comparable to our results. Prospective randomized study should be required in order to clarify the optimal timing of IFN- α treatment.

Our regimen produced a high response rate for untreated patients. Table 7 shows representative studies of chemotherapy and hematopoietic stem cell transplantation (BMT and PBSCT) that achieved high response rates¹⁻¹⁸. Despite wide-ranging treatment modalities, CR rates fall within the range of 22 to 30%, except for the study by Aviles. Although The results of our study are not inconsistent with these reports⁹⁻¹¹,

they and are superior to the others in regards to untreated patients (CR rate of 37%).

A recent breakthrough in massive chemotherapy involving hematopoietic stem cell transplantation, which promises to produce a high CR rate and longer survival time compared to chemotherapy, includes tandem transplantation involving two cycles of auto-PBSCT in a short period^{16,17}. However, transplantation is difficult to apply to the elderly (≥ 65 years old) or patients with organ disorders. In contrast, as chemotherapy is widely applicable, the DMVM-IFN- α therapy can be a choice for patients in any condition (old age or renal dysfunction).

Myeloma Trialists' Collaborative Group (MTCG) reported in 1998 that as a result of the meta-analysis of MP therapy versus combination chemotherapy (CCT), combina-

Table 6. Adverse reactions and abnormal laboratory findings

Number of adverse reactions	34/140 (24.3%)	
Number of and abnormal laboratory findings	76/140 (54.3%)	
Subjective or objective adverse reactions	Number of patients	Frequency (%)
Fever	11	7.9
Malaise	6	4.3
Headache	1	0.7
Depressed state	1	0.7
Delusion/unrest	1	0.7
Nausea/vomiting	2	1.4
Anorexia	1	0.7
Diarrhea	1	0.7
Heart burn/stomach upset	1	0.7
Stomatitis	1	0.7
Ocular gaudus hemorrhage (visual impairment), Abnormal ophthalmoscopic findings	2	1.4
Depilation	2	1.4
Interstitial pneumonia	1	0.7
Generalized erythroderma	1	0.7
Sudden deafness	1	0.7
Right scapulalgia	1	0.7
Abnormal laboratory findings		
Leukocytopenia	17	12.1
Thrombocytopenia	10	7.1
Anemia	5	3.6
Liver dysfunction	6	4.3
Hyperglycemia	4	2.9

tion chemotherapy improved response rates over MP but did not contribute to survival¹⁹. We suggest that not only the good remission status but also optimal maintenance treatment is required for the improvement of survival times.

Despite progress in therapy for MM, approximately 20% of patients are refractory to therapy. A cure for MM is hardly anticipated because survival curves have not reached plateaus in these studies. Following up prognosis of patients showing CR in these studies will disclose the probability of cure for MM.

In recent years, evidence has been accumulated for genetically unstable MM following a multi-step transformation process²⁰. In addition, several mechanisms of drug resistance in MM have been clarified²¹. It should be noted that MM is extremely susceptible to treatment resistance is very likely to develop in MM, thereby readily progressing to advanced stages. The current challenge in therapy for MM is in finding the way from CR to cure.

ACKNOWLEDGMENTS

We thank K. Nukui, H. Arano, and K. Hosokawa for their skillful assistance in statistical analysis.

REFERENCES

- 1 Barlogie B : Biology and therapy of multiple myeloma in 1996. *Semin Hematol* 34 (Suppl 1) : 67-72, 1997
- 2 Kitani T : New protocols for myeloma chemotherapy plus IFN- α . *Jap J Clin Hematol* 34 : 455-459, 1993
- 3 Barlogie B, Smith L, Alexanian R : Effective treatment of advanced multiple myeloma refractory to alkylating agents. *N Engl J Med* : 310, 1984
- 4 Alexanian R, Barlogie B, Tucker S : VAD-based regimens as primary treatment for multiple myeloma. *Am J Haematol* 33 : 86-89, 1990

Table 7. Comparison of therapeutic results that included CR

Treatment (reported by, year of latest report)	Effects (%)		50% remission period (months)				50% survival period (months)			Survival period	
	CR+PR	CR	CR+PR	CR	PR	All patients	CR+PR	CR	PR	All patients	CR
MP (Gregory 1992)	50-60	Rare				19-50 (mean 32.4)				2 years 58%	
Modified VAD (Samson 1989)	84	28	18	18*	18*	44	NM	NM	NM	2 years 75%	2years 90%
Modified VAD (Anderson 1995)	84	27	NM	NM	NM		36	NM	28	months	
High-dose melphalan therapy (Cunningham 1994)	82	32	18	NM*	NM*	47	NM	NM	NM	9 years 34.5%	
VBMCP+IFN- α (Oken 1996)	80	30	35	46	NM	42	NM	NM	NM	5 years 42%	4years 82%
CVMP/ CVNP/ BEVD+IFN- α (Aviles 1995)	80 (no PR)	80	32	32	—	#	#	#	—	5 years 72%	
ROAD-IN (Wada2000)	75	24	NM	NM	NM	3.6 (years)	4.3 (years)	NM	NM	7 years 26%	
DMVM+IFN- α (Kitani 2004)	76	27	15.1	21.2*	11.0*	38.1	45.8	46.9*	39.7*	5 years 34%	
atuo-BMT (Ataal 1996)	81	22	27	NM	NM	#	NM	NM	NM	5 years 52%	
Tandem autologous transplantation (Barlogie 1997)	85	40	49	NM	NM	62+	NM	NM	NM		
Tandem autologous transplantation (Attal 2003)	88	50	36	NM	NM	58	NM	NM	NM	7 years 42%	
allo-SCT (Gahrton 2001)										3 years	
1983-1994 : BMT	NM	54	NM	NM	NM	10	NM	NM	NM	35%	
1994-1998 : BMT		53				50				55%	
1994-1998 : PBSCT		50				□				57%	

These results were for previously untreated patients, except for allo-BMT (Gahrton) and our study. The survival period in patients who received transplantation was calculated from the beginning of transplantation by Gahrton *et al.* and from the beginning of the induction therapy before transplantation by Attal *et al.* NM : Not mentioned. # Survival rate ³ 50% at the time of investigation.¹⁹ * No significant difference between CR and PR.

5 Alexanian R, Dimopourous MA, Delasalle K, Barlogie B : Primary dexamethasone treatment of multiple myeloma. *Blood* 80 : 887-890, 1992

6 Cooper MR, Welander CE : Interferon in the treatment of multiple myeloma. *Cancer* 59 : 594-600, 1987

7 Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ Jr, Wilson HE : Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. *JAMA* 208 : 1680-1685, 1969

8 Gregory WM, Richards MA, Malpas JS : Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma : An overview of published trials. *J Clin Oncol* 10 : 334-342, 1992

9 Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, Joyner M, Aston L, Mitchell T, Hamon M, et al. : Infusion of vincristine and doxorubicin with oral dexamethasone at first line therapy for multiple myeloma. *Lancet* 2 : 882-885, 1989

10 Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS,

Morgenstern GR, Fitzsimmons L, Ryder D : VAD therapy as remission induction for multiple myeloma. *Brit J Cancer* 71 : 326-330, 1995

11 Wada M, Mizoguchi H, Kuriya SI, Taguchi H, Kawamura T, Maekawa I, Shimazaki C, Sato Y, Niho Y, Miyazaki T, Shibata A, Kitani T, Hamajima N, Ohno R : Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma : a co-operative study in Japan. *Br J Haematol* 109 : 805-814, 2000

12 Cunningham D, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicolson M, Meldrum M, Viner C, Milan S, Selby PJ, et al. : High-dose melphalan for multiple myeloma : Long-term follow up data. *J Clin Oncol* 12 : 764-768, 1994

13 Oken MM : Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN α 2b) in patients with multiple myeloma. *Leuk Lymphoma* 20 : 447-452, 1996

14 Aviles A : Alternating combination chemotherapy and interferon improves survival in poor prognosis multiple myeloma. *Clin*

- Oncol 7 : 97-101, 1995
- 15 Attal M : A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. *N Engl J Med* 335 : 91-97, 1996
 - 16 Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G : Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. *Blood* 89 : 789-793, 1997
 - 17 Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R ; InterGroupe Francophone du Myelome. : Single versus double autologous stem-cell transplantation for multiple myeloma. *N Engl J Med* 349 : 2495-2502, 2003
 - 18 Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, Blade J, Cornelissen J, de Laurenzi A, Facon T, Ljungman P, Michallet M, Niederwieser D, Powles R, Reiffers J, Russell NH, Samson D, Schaefer UW, Schattenberg A, Tura S, Verdonck LF, Vernant JP, Willemze R, Volin L ; European Group for Blood and Marrow Transplantation. : Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma : a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. *Brit J Haematol* 113 : 209-216, 2001
 - 19 Myeloma Trialists' Collaborative Group : Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma : an overview of 6,633 patients from 27 randomized trials. *J Clin Oncol* 16 : 3832-3842, 1998
 - 20 Hallek M, Bergsagel PL, Anderson KC : Multiple myeloma : Increasing evidence for a multistep transformation process. *Blood* 91 : 3-21, 1998
 - 21 Sonneveld P, Lokhorst HM, Vossebeld P : Drug resistance in multiple myeloma *Semin Hematol* 34 : 34-39, 1997